Page last updated: 2024-11-04

potassium iodide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Potassium iodide (KI) is an inorganic compound that is a white, odorless, crystalline salt that is readily soluble in water. It is synthesized by reacting potassium hydroxide with iodine. Potassium iodide is used in medicine as an expectorant to thin the mucus in the respiratory system, as a source of iodide for treating thyroid disorders, and as a radiation protectant to help protect the thyroid gland from radioactive iodine. It is also used in photography, where it is used to reduce silver halides in the development of photographic images. Potassium iodide is a significant component of table salt (iodized salt) and is studied extensively for its role in thyroid health, especially in the prevention of iodine deficiency disorders.'

Potassium Iodide: An inorganic compound that is used as a source of iodine in thyrotoxic crisis and in the preparation of thyrotoxic patients for thyroidectomy. (From Dorland, 27th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

potassium iodide : A metal iodide salt with a K(+) counterion. It is a scavenger of hydroxyl radicals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4875
CHEMBL ID1141
CHEBI ID8346
MeSH IDM0017380

Synonyms (135)

Synonym
AB01274864-01
AKOS015833375
nsc 77362
caswell no. 694
epa pesticide chemical code 075701
joptone
iodure de potassium
einecs 231-659-4
potassium salt of hydriodic acid
hsdb 5040
kalii iodidum
ai3-52931
tripotassium triiodide
potassium iodide (k3i3)
potassium iodide [jan]
potide
CHEBI:8346 ,
kaliumiodid
kisol
pima
wln: ka i
k1-n
nsc-77362
asmofug e
potassium diiodide
potassium monoiodide
potassium iodide (ki)
kali iodide
potassium iodide (k(i2))
dipotassium diiodide
potassium iodide (k2i2)
thyro-block
knollide
nsc77362
C08219
potassium iodide
7681-11-0
potassium iodide, plant cell culture tested
potassium iodide, bioxtra, >=99.0%
potassium iodide, anhydrous, beads, -10 mesh, 99.998% trace metals basis
thyroblock (tn)
potassium iodide (jp17/usp)
D01016
potassium iodide, >=99.99% trace metals basis
potassium iodide, puriss. p.a., acs reagent, >=99.0% (at)
potassium iodide, bioultra, >=99.5% (at)
DB06715
iodine (as potassium iodide)
iodine (as potassium)
kali iodatum
CHEMBL1141
iosat
iodide, potassium
NCGC00257542-01
tox21_301293
dtxcid5014836
cas-7681-11-0
dtxsid7034836 ,
P1721
unii-1c4qk22f9j
ec 231-659-4
kalium iodatum
1c4qk22f9j ,
potassium iodide [usp:jan]
ccris 8168
thyroshield
thyrosafe
FT-0645116
S1897
kalii iodidum [who-ip latin]
iodine (as potassium iodide) [vandf]
potassium iodide [orange book]
potassium iodide [fcc]
iodine (as potassium) [vandf]
potassium iodide [usp-rs]
potassium iodide [mart.]
potassium iodide [vandf]
potassium iodide [usp monograph]
potassium iodide [who-dd]
potassium iodide [mi]
potassium iodide [hsdb]
potassium iodide [inci]
potassium iodide [who-ip]
kali iodatum [hpus]
potassium iodide [ep monograph]
potassiumiodide
potassium-iodide
NLKNQRATVPKPDG-UHFFFAOYSA-M
potasium iodide
potassium iodid
AB01568251_01
mfcd00011405
potassium iodide, ultra dry
potassium iodide, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99%
potassium iodide, anhydrous, free-flowing, redi-dri(tm), reagentplus(r), 99%
potassium iodide, purum p.a., >=99.0% (at)
potassium iodide, saj first grade, >=99.5%
potassium iodide, puriss. p.a., reag. iso, reag. ph. eur., >=99.5%
potassium iodide, jis special grade, >=99.5%
potassium iodide, acs reagent, >=99.0%
potassium iodide, united states pharmacopeia (usp) reference standard
potassium iodide, suitable for oxidant determination, >=99.5%
potassium iodide, tested according to ph.eur.
potassium iodide, reagentplus(r), 99%
HMS3651G04
potassium iodide, ar, >=99.8%
potassium iodide, lr, >=99%
potassium iodide, pharmaceutical secondary standard; certified reference material
potassium iodide, acs reagent
potassium iodide, vetec(tm) reagent grade
CS-B1801
SW219147-1
potassium iodide, trace metals grade 99.99%
potassium iodide,(s)
gold etchant, standard
Q121874
potassium;iodide
CCG-266323
potassium iodide acs grade
k i (h2 o)2
potassium iodide, 99.5%
potassium iodide (usp-rs)
radiban
thyrojod
potassium iodide (mart.)
thyroblock
kali iodatum.
potassium iodide (ep monograph)
kali iodatum 1x
potassium iodide (usp:jan)
potasio ioduro
usepa/opp pesticide code: 075701
potassium iodide oral solution
potassium iodide (usp monograph)
Z104473300

Research Excerpts

Overview

Potassium iodide (KI) is a medication that has been used for decades in dermatology and it is mentioned as a treatment option in all major dermatology textbooks. It is an essential component of the treatment of systemic B.

ExcerptReferenceRelevance
"Potassium iodide (KI) is a medication that has been used for decades in dermatology and it is mentioned as a treatment option in all major dermatology textbooks. "( Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study.
Anzengruber, F; Dummer, R; Mergenthaler, C; Murer, C, 2019
)
3.4
"Potassium iodide is an essential component of the treatment of systemic B."( Gastro-intestinal basidiobolomycosis in a 2-year-old boy: dramatic response to potassium iodide.
Geramizadeh, B; Hosseini Khorami, H; Kadivar, MR; Khalifeh, M; Nasimfar, A; Pouladfar, G; Sanaei Dashti, A, 2018
)
1.43
"Potassium iodide (KI) is a useful drug in the dermatologic armamentarium. "( Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications.
Heymann, WR; Sterling, JB, 2000
)
3.19

Effects

Potassium iodide (KI) has traditionally been used to reduce gland vascularity and diminish blood loss in patients undergoing thyroidectomy for Graves disease (GD) No standard dosage has been established in children. Pot potassium iodide therapy has a history of more than 150 years.

ExcerptReferenceRelevance
"Potassium iodide therapy has a history of more than 150 years. "( Potassium iodide in erythema nodosum and other erythematous dermatoses.
Danno, K; Horio, T; Imamura, S; Miyachi, Y; Okamoto, H, 1983
)
3.15
"Potassium iodide (KI) has been reported to minimize such staining, but doubts remain over its long-term efficacy and potential adverse influence on the effectiveness of SDF."( A quantitative evaluation of the effects of potassium iodide on the clinical properties of silver diamine fluoride.
Kar, S; Rao, D; Samaddar, K; Zahir, S,
)
1.11
"Potassium iodide has been used in only a few cases, and no standard dosage has been established in children."( Potassium iodide in refractory, recurrent pediatric Sweet syndrome: Guidance in dosing and monitoring.
Drucker, A; Forse, C; Ho, N; Tangtatco, JAA, 2018
)
2.64
"Potassium iodide (KI) has traditionally been used to reduce gland vascularity and diminish blood loss in patients undergoing thyroidectomy for Graves disease (GD). "( Is potassium iodide solution necessary before total thyroidectomy for Graves disease?
Baker, A; Broome, JT; Shinall, MC; Solorzano, CC, 2013
)
2.45
"Potassium iodide therapy has a history of more than 150 years. "( Potassium iodide in erythema nodosum and other erythematous dermatoses.
Danno, K; Horio, T; Imamura, S; Miyachi, Y; Okamoto, H, 1983
)
3.15
"Potassium iodide (KI) has been shown to impair thyroid protein biosynthesis both in vivo and in vitro. "( Action of KI, thyroxine and cyclic AMP on [3H]uridine incorporation into the RNA of thyroid slices.
Aiello, LO; Kleiman de Pisarev, DL; Pisarev, MA, 1976
)
1.7
"Potassium iodide (KI) has been shown to have an antigoitrogenic action and to inhibit in vivo thyroid protein biosynthesis. "( Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis.
Aiello, LO; Pisarev, MA, 1976
)
1.97

Treatment

Potassium iodide (KI) treatment affects the vascularity of the thyroid gland and therefore may improve intraoperative visualization of essential structures. Oral treatment with potassium iodide, 8 mg x 3 times a day, was started at 23 days of life.

ExcerptReferenceRelevance
"Potassium iodide (KI) treatment affects the vascularity of the thyroid gland and therefore may improve intraoperative visualization of essential structures. "( Preoperative Potassium Iodide Treatment in Patients Undergoing Thyroidectomy for Graves' Disease-Perspective of a European High-Volume Center.
Fendrich, V; Kußmann, J; Lindner, K, 2020
)
2.37
"Potassium iodide is the treatment of choice in our center."( [Sporotrichosis: prevalence, clinical and epidemiological features in a reference center in Colombia].
Alvarado, Z; Porras, L; Rubio, G; Sánchez, G, 2010
)
1.08
"Potassium iodide (the treatment of choice in endemic areas) is an effective and inexpensive therapy; however, its adverse effects and complicated dosage regimen often weigh against its use in developed countries, where itraconazole is the antimycotic of choice."( Sporotrichosis.
Morris-Jones, R, 2002
)
1.04
"Treatment with Potassium iodide and co-trimoxazole is simple and effective."( Subcutaneous Basidiobolomycosis Resembling Fournier's Gangrene.
Mohanraj, P; Rajan, RJ; Rose, W, 2017
)
0.79
"His treatment with potassium iodide solution was complicated by the occurrence of subclinical hypothyroidism."( Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis.
Dunlap, DB; Fitch, MH; Lesher, JL, 1994
)
0.89
"Oral treatment with potassium iodide (KI, 8 mg x 3 times a day) was started at 23 days of life."( Efficacy of oral iodide therapy on neonatal hyperthyroidism caused by maternal Graves' disease.
Cafforio, C; Cavaliere, AF; Crescimbini, B; Florio, MG; Girlando, P; Maragliano, G; Noia, G; Scapillati, ME; Tortorolo, G; Zuppa, AA,
)
0.45
"Pre-treatment with potassium iodide reduced serum T4 to normal or subnormal in all patients."( The clinical and metabolic responses to early surgical treatment for hyperthyroid Graves' disease: a comparison of three pre-operative treatment regimens.
Browning, MC; Feely, J; Forrest, AL; Gunn, A; Hamilton, WF; Isles, TE; Peden, NR, 1985
)
0.59

Toxicity

ExcerptReferenceRelevance
"The effectiveness of toxic oxygen metabolites in killing the yeast form of Paracoccidioides brasiliensis (the form that occurs in host tissues) was studied with a fluorescence method in vitro."( Toxic effect of products of oxidative metabolism on the yeast form of Paracoccidioides brasiliensis.
Brummer, E; McEwen, JG; Restrepo, A; Stevens, DA; Sugar, AM, 1984
)
0.27
" In conclusion, 1) amiodarone had a cytotoxic effect in CHO fibroblasts, a nonthyroid cell line; 2) this cytotoxic effect occurred in thyroid cells independent of their ability to organify iodide; 3) however, the toxic effect of amiodarone was greater and occurred at a lower molar concentration in freshly prepared human thyroid follicles that trap and organify iodide; and 4) in the latter culture system, methimazole, an inhibitor of iodide organification, partially, but significantly, reduced the cytotoxic effect of amiodarone."( Studies on the in vitro cytotoxic effect of amiodarone.
Braverman, LE; Chiovato, L; Lapi, P; Mammoli, C; Martino, E; Pinchera, A; Santini, F; Tonacchera, M, 1994
)
0.29
" This article reviews the pharmacology, mechanism of action, indications, contraindications, and adverse effects of KI as a therapeutic agent."( Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications.
Heymann, WR; Sterling, JB, 2000
)
1.75
" Phenobarbital, Aroclor 1254 and beta-naphthoflavone (indirect toxic mechanism) enhanced thyroidal radioiodide accumulation, and the administration of potassium perchlorate had no effect on thyroid: blood (125)I ratio."( Standardization of the perchlorate discharge assay for thyroid toxicity testing in rats.
Coelho-Palermo Cunha, G; van Ravenzwaay, B, 2007
)
0.34
" Vaporized KMT reagent could be used for the safe and easy sterilization of cabinets contaminated with Bacillus spores."( Sterilization of a biological safety cabinet by vaporized KMT reagent.
Kida, N; Mochizuki, Y; Taguchi, F, 2007
)
0.34
"Exposure to iodinated contrast media may elicit a variety of adverse reactions."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" The important role of iodine in this adverse reaction is demonstrated."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" Potential adverse effects of ITB have not been systematically investigated so far."( Adverse effects of iodine thyroid blocking: a systematic review.
Krille, L; Reiners, C; Schneider, R; Spallek, L; Yamashita, S; Zeeb, H, 2012
)
0.38
"Methimazole (MMI) is usually used at an initial dose of 30 mg/day for severe Graves' disease (GD) hyperthyroidism, but adverse effects are more frequent at this dose than at MMI 15 mg/day."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
" MMI 30 mg/day (M30)) in terms of therapeutic effect, adverse effects, and remission rate."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
" Adverse effects that required discontinuation of MMI were more frequent in the M30-treated than in the M15+I-treated group (14."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
"The first therapeutic choice for the treatment of cutaneous sporotrichosis is oral itraconazole; however, the increase in cases of zoonotic transmission outbreak necessitates a search for effective and safe treatment alternatives."( New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients.
Bernardes-Engemann, AR; Lopes-Bezerra, LM; Macedo, PM; Orofino-Costa, R, 2015
)
0.76
" The incidence of adverse events was similar for both groups (64."( New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients.
Bernardes-Engemann, AR; Lopes-Bezerra, LM; Macedo, PM; Orofino-Costa, R, 2015
)
0.76
"Combination of itraconazole and SSKI is an effective treatment modality for RFC with relatively faster onset of action, low relapse rates, and minimal adverse effects."( A prospective case series evaluating efficacy and safety of combination of itraconazole and potassium iodide in rhinofacial conidiobolomycosis.
Dogra, S; Gupta, M; Kaur, RJ; Manhas, A; Narang, T; Saikia, UN, 2016
)
0.65

Pharmacokinetics

ExcerptReferenceRelevance
" Experiments on thyroidectomized and T4 substituted rats have demonstrated as an additional pharmacodynamic effect of Lith."( Antihormonal effects of plant extracts. Pharmacodynamic effects of lithospermum officinale on the thyroid gland of rats; comparison with the effects of iodide.
Kemper, FH; Sourgens, H; Winterhoff, H, 1983
)
0.27
" A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters."( Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats.
Agarande, M; Bouvier-Capely, C; Chioukh, R; Jourdain, JR; Legrand, A; Moulin, C; Phan, G; Rebière, F; Renaud-Salis, V; Sontag, T; Suhard, D, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"A patient with underlying Hashimoto's thyroiditis developed amiodarone-induced thyrotoxicosis type 1 that was successfully treated using methimazole in combination with potassium iodide."( Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis.
Hirose, T; Ikehara, K; Katoh, D; Kumashiro, N; Tsuboi, K; Uchino, H; Yoshino, H, 2020
)
0.97

Bioavailability

Study compared iodine bioavailability in iodine-replete adults. Measurement of 24-h urinary-free iodide indicated that the bioavailability of potassium iodide delivered by retention enema was at least 40%.

ExcerptReferenceRelevance
" Measurement of 24-h urinary-free iodide indicated that the bioavailability of potassium iodide delivered by retention enema was at least 40%."( Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm.
Balasubramanyam, A; Go, R; Yeung, SC, 1995
)
0.52
"Low bioavailability of mercury (Hg) in soil is a restricting factor in phytoextraction of Hg-contaminated soil."( Use of iodide to enhance the phytoextraction of mercury-contaminated soil.
Greger, M; Wang, Y, 2006
)
0.33
" There is a recent interest to use pluronic for improving the solubility and bioavailability of these drugs."( A fluorescence study on the interaction of telmisartan in triblock polymers pluronic P123 and F127.
Mishra, AK; Mohanty, ME; Rao, VJ, 2014
)
0.4
" However, to our knowledge, iodine bioavailability from milk has not been directly measured in humans."( Iodine bioavailability from cow milk: a randomized, crossover balance study in healthy iodine-replete adults.
Berard, J; Bürki, S; Galetti, V; Haldimann, M; Herter-Aeberli, I; Krzystek, A; van der Reijden, OL; Zeder, C; Zimmermann, MB, 2019
)
0.51
"The aim of this study was to compare iodine bioavailability in iodine-replete adults from: 1) cow milk containing a high concentration of native iodine; 2) milk containing a low concentration of native iodine, with the addition of potassium iodide (KI) to assess a potential matrix effect; and 3) an aqueous solution of KI as a comparator; with all 3 containing equal amounts of total iodine (263 µg/250 mL)."( Iodine bioavailability from cow milk: a randomized, crossover balance study in healthy iodine-replete adults.
Berard, J; Bürki, S; Galetti, V; Haldimann, M; Herter-Aeberli, I; Krzystek, A; van der Reijden, OL; Zeder, C; Zimmermann, MB, 2019
)
0.7
"Nearly all of the iodine in cow milk is iodide and although fractional iodine absorption from milk decreases with increasing dose, its bioavailability is high."( Iodine bioavailability from cow milk: a randomized, crossover balance study in healthy iodine-replete adults.
Berard, J; Bürki, S; Galetti, V; Haldimann, M; Herter-Aeberli, I; Krzystek, A; van der Reijden, OL; Zeder, C; Zimmermann, MB, 2019
)
0.51

Dosage Studied

Potassium iodide is an effective and inexpensive therapy. Its adverse effects and complicated dosage regimen often weigh against its use in developed countries.

ExcerptRelevanceReference
" So 1-thyroxine, depending on the dosage used, may stimulate the development of tumor process in mammary glands, but exert no influence on it (an effect of "the effect extinction"), and finely suppress tumor development."( [The influence of thyroid and antithyroid preparations on the development of induced breast cancer].
Beskrovnyĭ, AM; Sukacheva, OA, 1976
)
0.26
" Simplicity of the proposed technique for detoxication and the functional systems' improvement, diet-based dosage regulation make the technique useful for both treatment and prevention purposes."( [Clinical evaluation of intestinal absorption and use of potassium iodide in order to increase effectiveness of therapeutic measures in pneumoconiosis of coal miners].
Vankhanen, VV, 1991
)
0.53
" One hundred and eighty-six were given a dose adjusted for thyroid size and radioactive iodine uptake (Protocol 1), and a second group received the same dosage followed by antithyroid drug therapy plus potassium iodide for 15 days (Protocol 2)."( Comparison of RA 131I treatment protocols for Graves' disease.
DeGroot, LJ; Mangklabruks, A; McCormick, M, 1990
)
0.47
" The method was applied successfully to the analysis of various commercially available phenothiazines in different dosage forms."( Colorimetric determination of certain phenothiazine drugs by using morpholine and iodine-potassium iodide reagents.
el-Shabouri, SR; Mohamed, FA; Rageh, AM; Youssef, AF,
)
0.35
" For this purpose, potassium iodate was distributed, free-of-charge, to all salt mills and an iodate dosing spray was supplied without cost to small salt producers."( Towards the eradication of iodine-deficiency disorders in Brazil through a salt iodination programme.
Medeiros-Neto, GA, 1988
)
0.27
" No detectable change in T(4) deiodination rate was observed with these agents in the dosage ranges employed in this study."( A new method for the measurement of acute alterations in thyroxine deiodination rate in man.
Nicoloff, JT, 1970
)
0.25
" Either of the two were given in recommended dosage (100 mg stable iodine per 70 kg body weight) at -2, 0, +2, +4, +6, and +8 h after administration of tracer quantities of radioiodine (131I) to age-, weight-, and sex-matched rats."( Potassium iodate and its comparison to potassium iodide as a blocker of 131I uptake by the thyroid in rats.
Borkar, AV; Pahuja, DN; Rajan, MG; Samuel, AM, 1993
)
0.56
" Using specific blockade of this kinase, a dose-response inhibition of hyperosmolar NaCl-induced IL-8 synthesis was observed, similar to that in cells stimulated with IL-1."( Osmotic regulation of cytokine synthesis in vitro.
Dinarello, CA; Shapiro, L, 1995
)
0.29
" tid dosage of SSKI."( Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide.
Begue, RE; Bustamante, B; Cabezas, C; Holgado, W, 1996
)
0.54
"2%) of the individuals initially assigned to the qd and tid dosing schedule, respectively, were cured by the treatment."( Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide.
Begue, RE; Bustamante, B; Cabezas, C; Holgado, W, 1996
)
0.54
" However, if the balloon ruptures, 188Re-perrhenate is released into the circulation, causing high radiation dosing to the thyroid and stomach."( A comprehensive study on the blockage of thyroid and gastric uptakes of 188Re-perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis.
Hsieh, JF; Knapp, FF; Lin, WY; Tsai, SC; Wang, SJ; Yen, TC, 2000
)
0.31
" The KI dosage regimen should be adjusted for age at exposure."( Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine: a review.
Aurengo, A; Geoffroy, B; Le Guen, B; Verger, P, 2001
)
0.31
" A dose-response relationship needs confirmation on a larger cohort of patients to reach statistical value."( Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Brans, B; Dierckx, RA; Kaufman, JM; Laureys, G; Monsieurs, M; Thierens, H, 2002
)
0.54
" Potassium iodide (the treatment of choice in endemic areas) is an effective and inexpensive therapy; however, its adverse effects and complicated dosage regimen often weigh against its use in developed countries, where itraconazole is the antimycotic of choice."( Sporotrichosis.
Morris-Jones, R, 2002
)
1.22
" The present study demonstrates that a single oral administration of 38 mg of iodide produces a thyroid-blocking effect equivalent to that of 76 mg of iodide, suggesting that a reevaluation of the stable iodine dosage during radiation emergencies in iodine-rich areas such as Japan is warranted."( Thyroid blockade during a radiation emergency in iodine-rich areas: effect of a stable-iodine dosage.
Aoyagi, K; Ishigaki, J; Ishigaki, K; Mine, M; Nakamura, Y; Takamura, N; Yamashita, S, 2004
)
0.32
"A strong dose-response relationship was observed between radiation dose to the thyroid received in childhood and thyroid cancer risk (P<."( Risk of thyroid cancer after exposure to 131I in childhood.
Abrosimov, A; Anoshko, J; Astakhova, L; Bouville, A; Cardis, E; Chekin, S; Demidchik, E; Drozdovitch, V; Galanti, R; Goulko, G; Hoshi, M; Ito, M; Ivanov, V; Kesminiene, A; Khrouch, V; Korobova, E; Lushnikov, E; Maceika, E; Maksioutov, M; Malakhova, I; Masyakin, V; Nerovnia, A; Parshin, V; Parshkov, E; Piliptsevich, N; Pinchera, A; Polyakov, S; Shabeka, N; Shibata, Y; Suonio, E; Tenet, V; Tsyb, A; Vlassov, O; Williams, D; Yamashita, S; Zvonova, I, 2005
)
0.33
" Stability of the mixtures over time was monitored, as was the dosage uniformity across preparations."( Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studies.
Brower, J; Buhse, L; Doub, W; Machado, S; Martin, ES; Moore, T; Nasr, M; Nguyenpho, A; Pelsor, F; Reepmeyer, J; Roberts, R; Sadrieh, N; Schuirmann, DJ; Straughn, A; Toler, D; Yu, L, 2005
)
0.33
" The methods have been successfully applied to the determination of irbesartan in commercial dosage forms."( Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry.
Azmi, SN; Rahman, N; Siddiqui, MR, 2006
)
0.33
" KI was discontinued when patients showed normal free thyroxine (FT4) levels but MMI was continued with a tapering dosage until remission."( Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Amino, N; Fukata, S; Ito, M; Kubota, S; Kudo, T; Miyauchi, A; Nishihara, E; Sasaki, I; Takata, K, 2010
)
0.36
" In this work, we studied the indirect dosage of clozapine by selective electrode to the iodides for the optimization of an analytical protocol allowing therapeutic monitoring and the diagnosis of intoxication and/or overdose."( Development of a method of clozapine dosage by selective electrode to the iodides.
Douki, W; Najjar, MF; Teyeb, H, 2012
)
0.38
" Rats were administered (131)I- and 3 hours later dosed with either saline, 30 mg/kg of NH(4)ClO(4) or 30 mg/kg of KI."( Radioactive iodide (131 I-) excretion profiles in response to potassium iodide (KI) and ammonium perchlorate (NH4ClO4) prophylaxis.
Blount, B; Dallas, C; Fisher, J; Harris, C; Rollor, E; Valentin-Blasini, L; White, C, 2012
)
0.62
" Consequently, there are few scientific studies on the pharmacological aspects, dosage and efficacy of this drug."( Use of potassium iodide in dermatology: updates on an old drug.
Bernardes-Engemann, AR; Carvalhal, A; Costa, RO; Macedo, PM,
)
0.59
" Potassium iodide has been used in only a few cases, and no standard dosage has been established in children."( Potassium iodide in refractory, recurrent pediatric Sweet syndrome: Guidance in dosing and monitoring.
Drucker, A; Forse, C; Ho, N; Tangtatco, JAA, 2018
)
2.83
"5 mg potassium iodide (KI)/100-g body weight, which corresponded to 500 times of the physiological daily dosage of iodide for a period of 60 days, while the other six formed the control group."( Iodine in excess in the alterations of carbohydrate and lipid metabolic pattern as well as histomorphometric changes in associated organs.
Chakraborty, A; Chandra, AK; Saha, A; Sarkar, D, 2018
)
0.99
" The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI."( Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats.
Agarande, M; Bouvier-Capely, C; Chioukh, R; Jourdain, JR; Legrand, A; Moulin, C; Phan, G; Rebière, F; Renaud-Salis, V; Sontag, T; Suhard, D, 2018
)
0.48
" His clinical condition did not improve, therefore, we increased the dosage of prednisolone to 40 mg/day; however, his rash gradually expanded with papules and plaques."( A case of neutrophilic dermatosis with
Daisuke, N; Endo, Y; Furukawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Koike, Y; Nakamura, H; Okamoto, M; Origuchi, T; Otsuka, M; Shimizu, T; Sumiyoshi, R; Takatani, A; Tamai, M; Tsuji, S, 2019
)
0.51
"02) and the dosage was better known (16% versus 28%, p = 0."( Nuclear power plant: state of knowledge of the population living in the area of the Cattenom special intervention plan. A cross-sectional study.
Ayav, C; Guerci, B; Guillemin, F; Klein, M; Schweitzer, ML, 2020
)
0.56
" Dosing of drugs in age and population groups should be carried out by specialists in radiation medicine and radiation safety in accordance with internationally recognized guidelines."( PROBLEMATIC ASPECTS, COMPLICATIONS, MISCONCEPTIONS AND DEBATABLE ISSUES OF IODINE PROPHYLAXIS IN RADIATION EVENTS (REVIEW).
Afanasiev, DE; Chikalova, IG; Dombrovska, NS; Kaminskyi, OV; Kopylova, OV; Loganovska, TK; Muraviova, IM, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (152 Items)

ItemProcessFrequency
Condimentscore-ingredient75
Groceriescore-ingredient64
Saltscore-ingredient58
Iodised saltscore-ingredient48
Plant-based foods and beveragescore-ingredient33
Beveragescore-ingredient31
Plant-based foodscore-ingredient29
Dairy substitutescore-ingredient29
Milk substitutescore-ingredient27
Plant-based milk alternativescore-ingredient26
Plant-based beveragescore-ingredient26
Cereals and potatoescore-ingredient20
Oat-based drinkscore-ingredient19
Cereals and their productscore-ingredient19
Cereal-based drinkscore-ingredient17
Table saltscore-ingredient8
Sea saltscore-ingredient7
Soy-based drinkscore-ingredient5
Legume-based drinkscore-ingredient5
Legumes and their productscore-ingredient5
Mealscore-ingredient5
Snackscore-ingredient5
Pizzascore-ingredient4
Dried products to be rehydratedcore-ingredient4
Dried productscore-ingredient4
Dietary supplementscore-ingredient4
Saucescore-ingredient3
Pizzas pies and quichescore-ingredient3
Dehydrated beveragescore-ingredient3
en:Dairy substitutescore-ingredient3
Beverages and beverages preparationscore-ingredient2
Protein powderscore-ingredient2
Sweet snackscore-ingredient2
Appetizerscore-ingredient2
Salty snackscore-ingredient2
Bodybuilding supplementscore-ingredient2
Meal replacementscore-ingredient2
en:Margherita Pizzacore-ingredient2
en:Vegetarian pizzascore-ingredient2
Spicescore-ingredient1
Hamscore-ingredient1
Prepared meatscore-ingredient1
Meatscore-ingredient1
Meats and their productscore-ingredient1
Bullion Cubecore-ingredient1
Plant-based milkcore-ingredient1
fr:Sels roses de l'Himalayacore-ingredient1
Himalaya saltscore-ingredient1
Dipscore-ingredient1
en:soy-milkscore-ingredient1
Mixed plant milkscore-ingredient1
Кроасанcore-ingredient1
Кроасани с пълнежcore-ingredient1
en:Viennoiseriescore-ingredient1
Сладки закускиcore-ingredient1
Закускиcore-ingredient1
Croissant filled with chocolatecore-ingredient1
Filled croissantscore-ingredient1
Croissantscore-ingredient1
Viennoiseriescore-ingredient1
Saltcore-ingredient1
Potato crispscore-ingredient1
Crispscore-ingredient1
Chips and friescore-ingredient1
Bolognese-Soßecore-ingredient1
Nudelsaucen auf Fleischbasiscore-ingredient1
Nudelsoßencore-ingredient1
Fleischsoßencore-ingredient1
Saucencore-ingredient1
Auf Fleisch basierende Lebensmittelcore-ingredient1
Gewürzmittelcore-ingredient1
Pasta saucescore-ingredient1
Supplementcore-ingredient1
Puffed salty snacks made from maizecore-ingredient1
Puffed salty snackscore-ingredient1
Crackerscore-ingredient1
Laitscore-ingredient1
Produits laitierscore-ingredient1
Cheese substitutescore-ingredient1
Plant basedcore-ingredient1
Oatcore-ingredient1
Unsweetened plain soy-based drinkscore-ingredient1
en:oat-milkscore-ingredient1
en:Unshelled pumpkin seedscore-ingredient1
en:Pumpkin seedscore-ingredient1
en:Pumpkin seeds and their productscore-ingredient1
en:Pumpkin and Squash plant productscore-ingredient1
en:Seedscore-ingredient1
Alimente pe bază de plantecore-ingredient1
Alimente și băuturi pe bază de plantecore-ingredient1
arahcore-ingredient1
Coapte și Săratecore-ingredient1
Arahidecore-ingredient1
cerealcore-ingredient1
Breakfast cereals fortified with vitamins and chemical elementscore-ingredient1
Breakfast cerealscore-ingredient1
Breakfastscore-ingredient1
oat based drinkscore-ingredient1
Cereal-bascore-ingredient1
Cereal barscore-ingredient1
Barscore-ingredient1
en:Plant-based milk alterncore-ingredient1
en:Plant-based beveragescore-ingredient1
en:Milk substitutescore-ingredient1
en:Cereals and their productscore-ingredient1
en:Cereals and potatoescore-ingredient1
en:Plant-based foodscore-ingredient1
en:Beveragescore-ingredient1
en:Plant-based foods and beveragescore-ingredient1
en:Beverages and beverages preparationscore-ingredient1
en:Oat-based drinkscore-ingredient1
Gabona tejekcore-ingredient1
Névényi tejekcore-ingredient1
Növényi alapú italokcore-ingredient1
Tejpótlókcore-ingredient1
Gabonafélék és azok termékeicore-ingredient1
Gabona- és burgonyafélékcore-ingredient1
Növényialapú élelmiszerekcore-ingredient1
Italokcore-ingredient1
Növényi alapú élelmiszerek és italokcore-ingredient1
Plant-based-yogurtcore-ingredient1
Oat milk yogurtscore-ingredient1
Non-dairy yogurtscore-ingredient1
Non-dairy fermented foodscore-ingredient1
Non-dairy dessertscore-ingredient1
Dessertscore-ingredient1
Fermented foodscore-ingredient1
Pat milkscore-ingredient1
Oatmilkcore-ingredient1
Hafermilchcore-ingredient1
Getreidemilchcore-ingredient1
Pflanzenmilchcore-ingredient1
Pflanzliche Getränkecore-ingredient1
Milchersatzcore-ingredient1
Getreideproduktecore-ingredient1
Getreide und Kartoffelncore-ingredient1
Pflanzliche Lebensmittelcore-ingredient1
Getränkecore-ingredient1
Pflanzliche Lebensmittel und Getränkecore-ingredient1
en:flakescore-ingredient1
en:Pizzascore-ingredient1
en:Pizzas pies and quichescore-ingredient1
en:Mealscore-ingredient1
en:Pizzas - hartige taarten en quichescore-ingredient1
en:Pizza Margheritacore-ingredient1
en:Kant-en-klaar maaltijdencore-ingredient1
en:Diepvriesproductencore-ingredient1
en:Diepvriespizzas en -taartencore-ingredient1
en:Diepvriespizzascore-ingredient1
Pizas tortas e quichescore-ingredient1
Refeiçõescore-ingredient1
protcore-ingredient1

Roles (2)

RoleDescription
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
expectorantCompounds that are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. Compare with mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration, and antitussives, which suppress the cough reflex.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
potassium saltAny alkali metal salt having potassium(1+) as the cation.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki300.00000.00001.372610.0000AID552171
Carbonic anhydrase 2Homo sapiens (human)Ki26,000.00000.00000.72369.9200AID552172
Carbonic anhydrase 4Homo sapiens (human)Ki80.00000.00021.97209.9200AID552173
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki25,000.00000.00001.27259.9000AID552169
Carbonic anhydrase 9Homo sapiens (human)Ki7,000.00000.00010.78749.9000AID552168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID552173Inhibition of human carbonic anhydrase 4 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552168Inhibition of human carbonic anhydrase 9 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID69151Compound was tested for its ability to inhibit DNA strand scission induced by resveratrol and Cu2+, at concentration 50 mM1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Resveratrol as a new type of DNA-cleaving agent.
AID552169Inhibition of human carbonic anhydrase 5 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552170Inhibition of Dicentrarchus labrax alpha-carbonic anhydrase by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552172Inhibition of human carbonic anhydrase 2 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552171Inhibition of human carbonic anhydrase 1 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,953)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901040 (53.25)18.7374
1990's241 (12.34)18.2507
2000's274 (14.03)29.6817
2010's283 (14.49)24.3611
2020's115 (5.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.67 (24.57)
Research Supply Index7.71 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index215.59 (26.88)
Search Engine Supply Index3.89 (0.95)

This Compound (62.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (3.25%)5.53%
Reviews96 (4.46%)6.00%
Case Studies284 (13.19%)4.05%
Observational4 (0.19%)0.25%
Other1,699 (78.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]